Literature DB >> 14683431

Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics.

Margret R Hoehe1, Bernd Timmermann, Hans Lehrach.   

Abstract

The identification of genes predisposing to human diseases is of paramount importance for understanding the molecular basis of the disease and individually different drug response, and will establish new routes to diagnosis and therapeutic advances of immense medical benefit. A key step common to all strategies for disease gene identification is the systematic analysis of candidate gene sequences to identify specific sequence variations associated with disease or any other phenotype of pharmaceutical relevance. In this article, current concepts and approaches to haplotype-based candidate gene analysis are reviewed. Moreover, a comprehensive summary of recent studies and data on the amount, nature, pattern and structure of genetic variation in candidate genes is given. These data demonstrate altogether remarkable gene sequence and haplotype diversity. Numerous individually different forms of a gene may exist. This presents challenges to the traditional views of the concept of "a" gene with far-reaching implications on the functional analysis of candidate gene variation, on the establishment of "sequence"-"structure"-"function" and complex haplotype/genotype-phenotype relationships, on the identification, evaluation and prioritization of drug targets and the concept of a "personalized medicine" in general. Moreover, present and future approaches to the identification of candidate and disease genes will be addressed. These include whole genome-based approaches such as integrative genomics as well as functional genomics-based approaches to analyze and model complex biological and medical processes. The analysis of whole complex systems in particular will provide the basis to make "maximally informed" guesses on candidate genes and address complex variability patterns in genes as well as complex genotype-phenotype relationships comprehensively at an advanced level.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14683431     DOI: 10.2174/1389201033377300

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  10 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

3.  [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].

Authors:  J Lötsch; R Freynhagen; G Geisslinger
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

4.  Genomic and geographic distribution of private SNPs and pathways in human populations.

Authors:  Tesfaye M Baye; Russell A Wilke; Michael Olivier
Journal:  Per Med       Date:  2009-11-01       Impact factor: 2.512

5.  Genetic variation and pharmacogenomics: concepts, facts, and challenges.

Authors:  Margret R Hoehe; Thomas Kroslak
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

6.  Haplotype and minimum-chimerism consensus determination using short sequence data.

Authors:  Shawn T O'Neil; Scott J Emrich
Journal:  BMC Genomics       Date:  2012-04-12       Impact factor: 3.969

7.  Inter-chromosomal variation in the pattern of human population genetic structure.

Authors:  Tesfaye M Baye
Journal:  Hum Genomics       Date:  2011-05       Impact factor: 4.639

Review 8.  Human genomic diversity, viral genomics and proteomics, as exemplified by human papillomaviruses and H5N1 influenza viruses.

Authors:  Meena K Sakharkar; Kishore R Sakharkar; Vincent T K Chow
Journal:  Hum Genomics       Date:  2009-07       Impact factor: 4.639

9.  Candidate genes for antidepressant response to selective serotonin reuptake inhibitors.

Authors:  Francis E Lotrich; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

10.  A graph-based algorithm for estimating clonal haplotypes of tumor sample from sequencing data.

Authors:  Yixuan Wang; Xuanping Zhang; Shuai Ding; Yu Geng; Jianye Liu; Zhongmeng Zhao; Rong Zhang; Xiao Xiao; Jiayin Wang
Journal:  BMC Med Genomics       Date:  2019-01-31       Impact factor: 3.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.